Pharma & Biotech

Zambia's flagship pharma plant sits on 40 acres at Lusaka South MFEZ. Its cleanroom air package is being scoped now. Who buys HVAC, and how.

Zambia's first injectable line is rising at Lusaka South MFEZ behind a USD 50M government offtake deal, commercial output targeted 2028.

Zambia licenses ten drugmakers; only four produce today, and a fifth is building at Lusaka South. Who buys tablet presses, and how deals get paid.

Zambia's blister-line buyers spec against ZAMRA's GS1 traceability rules; MFEZ machinery clears customs duty and VAT free versus 16% VAT outside it.

Zambia's first large-scale pharma plant is rising at Lusaka South MFEZ behind a USD 50M offtake deal. The equipment RFQs, buyers, and payment routes.

No injectable filling line is built in Uganda. Where used and modular sterile lines come from, what an 11,500 m2 BFS incumbent means, and landed cost.

QCIL's second Luzira plant will lift output from 1.4 to 2.4 billion tablets, and its cleanroom air package is being scoped now. Who buys HVAC in Uganda.

Uganda's biggest tablet maker is doubling capacity to 2.4 billion a year. Who buys presses and blister machines in Kampala and how deals get paid.

Uganda imports 90% of its medicines and charges a 12% verification fee on 37 locally made lines. Where the pharma equipment RFQs sit and who signs.

Kenya makes 694 medicine formulations and almost no active ingredients. A Sh27.8bn Konza park wants to change that. What reactor buyers specify.

Kenyan pharma plants run at under 50% of capacity and face GS1 unit-level serialisation from January 2027. What that changes in a blister line bid.

Kenya's medicine import bill hit Sh99.8bn in 2024 and only 220 of 1,096 essential formulations are made locally. Where the equipment RFQs sit.

Kenya's vaccine requirement runs near KSh 8 billion a year, all imported. What a used or modular pharmaceutical freeze dryer is actually worth.

Kenya's manufacturing strategy prices a sterile injectable plant at Sh800m. Where vial, ampoule and liquid filling RFQs sit and who signs them.

Sanofi committed over EUR 2.5B to French biologics. How GTP Bioways, Cenexi and peers win mAb and biosimilar contracts beyond CPHI.

France is set to launch 44 new cell and gene therapies by 2030. How French CDMOs win ATMP, CAR-T, and viral vector mandates from global sponsors.

France produces 3.5B boxes of medicines a year, with one player holding 32% of generics. Here is how French generics makers reach international buyers.

France runs 271 pharma plants and is Europe's #2 in biomedicines. Inside the French fill-finish CDMO field and how to reach drug-product buyers.

France exported $9.53B of vaccines and biologicals in 2024. How French vaccine manufacturers reach global procurement buyers in 2026.

Swiss antibody-drug conjugate CDMOs sit on a market projected to hit $15.4B in 2026. Here is how Cerbios, Lonza, ADC Therapeutics and Araris compete.

Swiss pharma exports hit CHF 118.4B in 2025. Inside the API and fine-chemicals manufacturers building global pipeline as Europe reshores production.

Swiss biologics CDMOs anchor a CHF 57.4B immunological export engine. How Lonza, Celonic and specialty players win clients beyond CPHI.

Swiss hormone and steroid exports under HS 2937 hit $971M in 2024, lifted by GLP-1 demand. How peptide CDMOs and steroid producers reach buyers.

The global mAb market hit $286B in 2025. Swiss manufacturers in Basel and Visp produce a large share. Here is how they build pipeline.

The oligonucleotide market hits USD 5.42B in 2026 at 13.14% CAGR. How Swiss CDMOs like Bachem and Microsynth win therapeutic-grade contracts.

The global peptide CDMO market hits $9B by 2036. How Bachem, PolyPeptide, and Lonza can build direct pipeline beyond GLP-1 anchor contracts.

The vaccine contract manufacturing market hits USD 5.24B in 2026. How Swiss fill-finish CDMOs win biologics and vaccine drug-product mandates.

A full GMP capsule line into Ghana runs USD 80,000 to 450,000 plus install. Here is how the budget breaks down, and how buyers pay for it.

Ghana imports over 70% of its medicines, and policy now reserves paracetamol syrup for local plants. How to scope an oral-liquid filling line.

Ghana imports over 70% of its medicines and 99% of its vaccines. Here is how foreign equipment suppliers reach the buyers building local capacity.

Ghana imports over 70% of its medicines, and every plant closing that gap needs WFI, cleanroom HVAC, and clean steam first. Who buys, and how to reach them.

Ghana imports over 70% of its medicines, and local plants are re-tooling oral-dose lines. How tablet press suppliers reach the named buyers.

Ghana imports 99% of its vaccines and is building local fill-finish lines for 600 million doses a year. Here is who buys the kit and how to reach them.

Morocco's pharma output rose 28.9% in Q4 2025. How to import ISO 5 cleanroom HVAC: customs, FX, GMP grades, and the buyers who issue the RFQ.

Morocco's pharma output jumped 28.9% in Q4 2025, the fastest-growing manufacturing sector. How equipment suppliers reach the buyers behind that build-out.

Morocco's pharma output grew 28.9% in Q4 2025. A buyer's guide to sourcing pharmaceutical lyophilisers: specs, payment, and the plants buying them.

Sothema's sterile area runs 60M injectable units a year and MARBIO is a USD 500M build. How to win Morocco's fill-finish line RFQs.

Morocco runs ~350 million units per shift in solid-dose capacity. How tablet-press and blister-line suppliers reach the buyers behind the build-out.

Importing a lyophilisation freeze drying system into South Africa: 15% VAT, FX and LC mechanics, freight, and IQ/OQ/PQ install in one guide.

Sourcing cleanroom HVAC and isolators for SA sterile pharma? Specs, a 4-OEM shortlist, indicative pricing, and the procurement workflow.

Used and modular sterile fill-finish lines into South Africa: 5 sourcing channels, the GMP requalification workflow, and freight realities for buyers.

SA's generics market hit $1.84B in 2025 and imports nearly all its tablet presses. Here's the supplier map, FX mechanics, and how to get quotes.

Canada has CAD $14.5B in pharma exports, up 38% since 2019. Here's how CDMOs and CMOs can reach qualified international buyers faster.

23.8% of German pharma exports went to the USA in 2024. How API, CDMO and generics producers widen their buyer base beyond ACHEMA.

Mexico's $4.39B API market is growing at 6% CAGR. Here is how generic drug and API manufacturers find international buyers.

Mexican pharma exports slipped to $2.33B in 2025 while plant investment rose. Here is how manufacturers rebuild export pipeline in 2026.

Turkey's pharma sector exports $2.27B to 186 countries from 109 production facilities. Why distributor dependency caps growth and what to do about it.

US biologics manufacturers sit on a $200B+ domestic market but still chase international buyers through trade shows and field reps.

US veterinary pharma hit $15.76B in 2025. Most animal health exporters still rely on VMX booths and field reps for buyers.